Navigation Links
EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
Date:10/25/2007

Results Consistent with MKC-1 Akt-mTOR Inhibitor Mechanism

ROCKVILLE, Md., Oct. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of results for its cell cycle inhibitor, MKC-1, in preclinical renal cell carcinoma (RCC) models. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Activation of the oncogenic kinase Akt and the mTOR pathway are known to be adverse prognostic factors and contributors to the pathology of metastatic RCC, therefore inhibitors of these pathways are of significant interest for treatment of this disease. Human RCC cell lines in vitro were shown to have marked sensitivity to MKC-1. MKC-1 inhibited both Akt and mTOR pathway activation in vitro, and was further evaluated in a preclinical model consisting of a xenograft of the human RCC cell line, Caki-1. Orally- administered MKC-1, but not sunitinib malate (Sutent(R)), significantly increased survival of tumor-bearing animals in this model. Examination of tumors following five days of oral treatment with MKC-1 revealed inhibition of the Akt-mTOR pathway, as well as decreased angiogenesis and cell proliferation within the tumors. These preclinical results support further evaluation of MKC-1 for the treatment of renal cell carcinoma.

MKC-1 is a novel, orally-active cell cycle inhibitor with in vitro and in vivo efficacy aga
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
7. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... BRIDGEWATER, N.J. , Dec. 15, 2014   ... SAN and NYSE: SNY) are collaborating with nationally-recognized patient ... Counts , an awareness program that will gauge how ... risks associated with high LDL-C (bad cholesterol).  American adults ... to take a brief poll and answer a few ...
(Date:12/15/2014)... --  DaVita HealthCare Partners Inc.  (NYSE: ... most innovative health care communities, today announced that ... Research  (DCR) and  HealthCare Partners Clinical Research , will ... research and data analytics services, specifically in patients ... disease (ESRD), as well as primary care and ...
(Date:12/13/2014)... December 12, 2014 ... the addition of the  "Global Catheters Market ... Global Trends, Company Profiles, Analysis, Segmentation and ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... up of medical grade material such as ...
Breaking Medicine Technology:Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4Global Catheters Market (Product Types and Geography) - Forecast to 2020 2Global Catheters Market (Product Types and Geography) - Forecast to 2020 3
... Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... treat voiding dysfunctions, announced today that its President and CEO ... on Tuesday, June 7, 2011.  The ceremony, held at the ... be broadcast live beginning at 3:45 p.m. ET via the ...
... 6, 2011 University Hospitals (UH) Seidman Cancer ... hospital, opens to patients on June 6. The ... cancer-fighting treatments and technology – all in a ... ) The $260 million, 375,000-square-foot ...
Cached Medicine Technology:Uroplasty's Dave Kaysen to Ring NASDAQ Closing Bell 2University Hospitals Seidman Cancer Center Opens: First Cancer Hospital in Northeast Ohio Offers Nation's Most Advanced Technology and Treatments 2University Hospitals Seidman Cancer Center Opens: First Cancer Hospital in Northeast Ohio Offers Nation's Most Advanced Technology and Treatments 3
(Date:12/17/2014)... (PRWEB) December 17, 2014 Dr. Myo Nwe ... Weight Loss Diet of the Future” and co-founder of the ... her book, Dr. Nwe takes a broad look at the ... hold up under scientific scrutiny. On film and in television ... emphasized mostly toward the social aspects and played for basic ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 In its ... and its Argus Claim Review division have recently ... the most common ways savings are achieved on behalf ... attributes millions of dollars in savings to Argus each ... 2013. , As explained by Tom Doney, Cypress president ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. ... diseases, one worrisome phenomenon is when an illness that originated ... known as zoonosis -- is not uncommon and keeps researchers ... animal-borne disease might make inroads into the human population. ... and the culprits in this case were guinea pigs. More ...
(Date:12/17/2014)... Amy Norton HealthDay Reporter ... long been believed to improve overall health, but a growing ... the heart, a new review finds. In fact, the ... brisk walking, said lead researcher Paula Chu, a doctoral candidate ... review, of 37 clinical trials, found that people randomly assigned ...
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ), Unionville’s first ... study providing evidence on the impact of 100% pure ... Sufficient enough evidence already exists showing a negative link ... with the onset of tooth decay. One question that ... 100% fruit juice, meaning it is completely natural with ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
... NEW YORK, March 4, 2011 Despite significant investment in ... has seen a marked decline in the number of ... at the New York Academy of Sciences on Wednesday, ... experts in clinical, translational, and basic neuroscience to address ...
... By Ellin Holohan HealthDay Reporter , THURSDAY, ... chance of getting a kidney transplant than whites do, claims ... used to decide who gets which donated organs. The ... that once "waitlisted" for a needed kidney, white patients were ...
... - DNA provides the instruction manual for all life ... and bad messages are sent leading to the creation ... , Paul Doetsch, PhD, professor of radiation oncology and ... Winship Cancer Institute and Damien Brgeon, PhD, at Institut ...
... Dr. David Levin, Professor of Molecular & Cell ... Dental Medicine and Professor of Microbiology at Boston University ... mechanism for the regulation of gene expression. The study ... Paf1 Complex Blocks Sen1-Mediated Premature Transcription Termination," appears in ...
... on producing radiation inside a tumour using,boron-10 and thermal ... help of a special carrier substance (phenylalanine), after which ... react with the boron to generate high-LET radiation, which ... treatment sessions may be sufficient to destroy a tumour, ...
... Congress on Osteoporosis & Osteoarthritis - the most ... held in Valencia,s award-winning ,Palacio de Congresos, from ... to take advantage of lower registration fees. ... world,s top bone experts, Learn about key topics in ...
Cached Medicine News:Health News:White Patients Most Likely to Get Kidney Transplants: Study 2Health News:White Patients Most Likely to Get Kidney Transplants: Study 3Health News:Nature Reviews Cancer article traces possible role of damaged DNA in tumor development 2Health News:Novel mechanism for control of gene expression revealed 2Health News:BNCT, a new-generation radiation treatment, is effective in advanced head and neck cancer 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: